Best Practice & Research Clinical Rheumatology
Volume 20, Issue 5 , Pages 949-967, October 2006

Spondyloarthropathy: disease at the crossroads of immunity

  • Oliver FitzGerald, MD FRCPI FRCP(UK) (Newman Clinical Research Professor)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +353 1 277 3721; Fax: +353 1 269 7949.

St. Vincent's University Hospital, Elm Park, Dublin, 4, Ireland

Centre for Rheumatic Diseases, Glasgow Royal Infirmary, 10 Alexandra Parade, Glasgow G31 2ER, UK

Up until recently, the prevailing paradigm relating to spondyloarthropathy (SpA) pathogenesis was that they were human leukocyte antigen (HLA)-associated, T-cell-driven autoimmune diseases. This view is now being questioned. Careful studies of well-characterised cohorts of patients with SpA, including detailed analysis of involved tissue, together with clinical trials of targeted treatments, in particular anti-tumour necrosis factor (TNF) therapies, have contributed enormously to both interest in and understanding of disease pathogenesis. In this chapter, our current knowledge and understanding of the relative contributions of the components of the innate and adaptive arms of the immune response to SpA pathogenesis is reviewed. It is clear that both arms of the immune response are involved and inter-dependent in SpA. With continued emphasis on discovery research, including detailed analysis of novel therapeutic interventions, significant additional breakthroughs in SpA are likely to be forthcoming.

Key words: adaptive immunity, innate immunity, cytokine, T lymphocyte, synovitis

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6942(06)00081-7

doi:10.1016/j.berh.2006.06.010

Best Practice & Research Clinical Rheumatology
Volume 20, Issue 5 , Pages 949-967, October 2006